From Trial to Practice: Validating Cellular Therapy in the Real World

This segment turns to the emerging real-world evidence that is validating what was first observed in pivotal clinical trials. The faculty walk through two complementary retrospective analyses: a multicenter effort capturing patients who successfully received therapy across several institutions, and a single-center study that illuminates the referral journey and the points at which patients may become ineligible. Together, these datasets reinforce encouraging response rates and durable benefit in a broader, more heterogeneous population than the original trials, including patients with serious disease characteristics. Importantly, no new safety signals emerged. The discussion emphasizes that patients who reach infusion can expect activity paralleling trial results, while also highlighting the real-world challenges of identifying candidates early and moving them efficiently through a complex pipeline. The experts reflect on how representative these findings are of everyday practice and what they mean for referral decisions.